Robert Harrington to Diabetes Mellitus, Type 2
This is a "connection" page, showing publications Robert Harrington has written about Diabetes Mellitus, Type 2.
Connection Strength
0.569
-
Cost-effectiveness of ticagrelor in patients with type 2 diabetes and coronary artery disease: a European economic evaluation of the THEMIS trial. Eur Heart J Cardiovasc Pharmacother. 2022 Dec 02; 8(8):777-785.
Score: 0.111
-
External applicability of the Effect of ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) trial: An analysis of patients with diabetes and coronary artery disease in the REduction of Atherothrombosis for Continued Health (REACH) registry. Int J Cardiol. 2023 Jan 01; 370:51-57.
Score: 0.110
-
Ticagrelor in Patients with Stable Coronary Disease and Diabetes. N Engl J Med. 2019 Oct 03; 381(14):1309-1320.
Score: 0.089
-
Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. Lancet. 2019 Sep 28; 394(10204):1169-1180.
Score: 0.089
-
Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study. Clin Cardiol. 2019 May; 42(5):498-505.
Score: 0.086
-
Obesity, Diabetes, and Acute Coronary Syndrome: Differences Between Asians and Whites. Am J Med. 2017 10; 130(10):1170-1176.
Score: 0.075
-
Clinical decisions. Management of stable coronary disease. N Engl J Med. 2007 Oct 25; 357(17):1762-6.
Score: 0.010